Company Overview and News

1
U.S. IPO Weekly Recap: 4 Small IPOs Price Ahead Of August Doldrums

2018-08-11 seekingalpha
The IPO market's very active summer 2018 has wrapped up. This week, four small IPOs got in before the annual August pause. Each priced below the midpoint to raise a combined $307 million. A regional airline, two regional banks, and biotech averaged a 0% return. Top performer Amalgamated Bank (AMAL) finished with a mere 6% gain, and the other three were negative. Trading was poor, but that came as no surprise to our institutional research clients (the deals didn't screen out particularly well on IPO Pro's MUSCLE Method, either).
SPAQ PCB MSRPW MESA AMAL VCNX APO PFCF

27
U.S. IPO Week Ahead: 5 IPOs Feature Regional Banks And A Regional Airline

2018-08-04 seekingalpha
A handful of small IPOs are set to price before the August break, with five raising less than $400 million.
MSRPW AMAL SPOT AAL ATH UAL PFCF

401
Stocks To Watch: Meet The New Ford

2018-08-04 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY AMAL RUTH BECN QES WHR HABT VIAB STI-A TSN WING SNAP MRCY WHD JCOM NWSA GPRE CRSP MDT REV GPK ZOES VCTR MGM WSO DFRG CTB OLED RAD GMVHF TEN HMI FLBD AGN CL AAPL UCBI KO USAP CBS GJV RRGB MUSA MCHP DDD "QES" VC TSLA CAKE APTV VPG BYD ARHVF EAT XON AMRS BLMN LDOS CVS UAL AMZN AIT NDSN CABO UPS KDP AAL CARS BR STE MAR REVG STI CLX BKEP TXRH DAN PG YELP TREC CDLX STMP ANDV MAR.WI MYL TSNU NWS KWR GM DIN FRPT DIS ECL F M FDX K BMI TGT ZG BKNG EOLS THRM DPZ ORLY

0
Amalgamated Bank Files Proposed Terms For IPO

2018-08-03 seekingalpha
Amalgamated Bank's selling shareholders intend to sell $107 million of Class A shares in a U.S. IPO.
AMAL NWBN

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...